OraSure Technologies, Inc, together with its subsidiaries, develops, manufactures, markets, and sells oral fluid diagnostic products and specimen collection devices in the United States, Europe, and internationally. It operates in two segments, OSUR and DNAG. The company also offers other diagnostic products, such as immunoassays and other in vitro diagnostic tests.
Read More…
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryHealth Care Supplies
SectorMedical
Phone610-882-1820
Debt
Price-To-Earnings
Sales & Book Value
Annual Sales$181.74 million
Profitability
Miscellaneous
Employees398
Next Earnings Date11/6/2019 (Estimated)
OptionableOptionable
OraSure Technologies (NASDAQ:OSUR) Frequently Asked Questions
What is OraSure Technologies' stock symbol?
OraSure Technologies trades on the NASDAQ under the ticker symbol "OSUR."
How were OraSure Technologies' earnings last quarter?
OraSure Technologies, Inc. (NASDAQ:OSUR) issued its earnings results on Tuesday, August, 6th. The medical instruments supplier reported $0.07 earnings per share (EPS) for the quarter, topping the Thomson Reuters' consensus estimate of $0.03 by $0.04. The medical instruments supplier had revenue of $38.83 million for the quarter, compared to analysts' expectations of $41.48 million. OraSure Technologies had a net margin of 11.83% and a return on equity of 7.81%. The firm's quarterly revenue was down 11.0% on a year-over-year basis. During the same period in the prior year, the business earned $0.07 EPS. View OraSure Technologies' Earnings History.
When is OraSure Technologies' next earnings date?
What guidance has OraSure Technologies issued on next quarter's earnings?
OraSure Technologies issued an update on its FY19 earnings guidance on Tuesday, August, 6th. The company provided earnings per share guidance of $0.24-0.26 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $0.25. The company issued revenue guidance of $165-170 million, compared to the consensus revenue estimate of $172.81 million.
What price target have analysts set for OSUR?
1 analysts have issued 12 month price targets for OraSure Technologies' shares. Their forecasts range from $7.00 to $7.00. On average, they anticipate OraSure Technologies' share price to reach $7.00 in the next year. This suggests that the stock has a possible downside of 8.4%. View Analyst Price Targets for OraSure Technologies.
What is the consensus analysts' recommendation for OraSure Technologies?
1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for OraSure Technologies in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for OraSure Technologies.
What are Wall Street analysts saying about OraSure Technologies stock?
Here are some recent quotes from research analysts about OraSure Technologies stock:
- 1. Canaccord Genuity analysts commented, "We stick with our HOLD rating and lower our PT from $9 to $7." (8/14/2019)
- 2. According to Zacks Investment Research, "OraSure Technologies, Inc. develops, manufactures and markets oral fluid specimen collection devices using proprietary oral fluid technologies, diagnostic products including immunoassays and other in vitro diagnostic tests, and other medical devices. These products are sold in the United States as well as internationally to various clinical laboratories, hospitals, clinics, community-based organizations and other public health organizations, distributors, government agencies, physicians' offices, and commercial and industrial entities. OraSure Technologies is the leading supplier of oral-fluid collection devices and in vitro diagnostic assays to the employment, criminal justice, drug treatment, life insurance and public health markets for the detection of abused drugs and the antibodies to HIV. Based in Bethlehem, Pennsylvania, the Company develops, manufactures and markets oral specimen collection devices, in vitro diagnostic tests, and other medical devices. " (7/9/2019)
Has OraSure Technologies been receiving favorable news coverage?
Press coverage about OSUR stock has been trending negative this week, according to InfoTrie Sentiment Analysis. InfoTrie ranks the sentiment of press coverage by analyzing more than six thousand blog and news sources in real time. The firm ranks coverage of public companies on a scale of -5 to 5, with scores closest to five being the most favorable. OraSure Technologies earned a coverage optimism score of -2.9 on InfoTrie's scale. They also assigned news stories about the medical instruments supplier a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the stock's share price in the immediate future. View News Stories for OraSure Technologies.
Are investors shorting OraSure Technologies?
OraSure Technologies saw a increase in short interest in August. As of August 15th, there was short interest totalling 3,087,300 shares, an increase of 15.6% from the July 15th total of 2,671,400 shares. Based on an average daily trading volume, of 618,800 shares, the days-to-cover ratio is presently 5.0 days. Approximately 5.2% of the shares of the stock are sold short. View OraSure Technologies' Current Options Chain.
Who are some of OraSure Technologies' key competitors?
Some companies that are related to OraSure Technologies include Cardiovascular Systems (CSII), Merit Medical Systems (MMSI), Atrion (ATRI), Cryolife (CRY), Silk Road Medical (SILK), Tactile Systems Technology (TCMD), AtriCure (ATRC), Luminex (LMNX), Orthofix Medical (OFIX), Shockwave Medical (SWAV), Axonics Modulation Technologies (AXNX), Anika Therapeutics (ANIK), Cerus (CERS), LeMaitre Vascular (LMAT) and AngioDynamics (ANGO).
What other stocks do shareholders of OraSure Technologies own?
Who are OraSure Technologies' key executives?
OraSure Technologies' management team includes the folowing people:
- Dr. Stephen S. Tang, Pres, CEO & Director (Age 58)
- Mr. Jack E. Jerrett, Sr. VP, Gen. Counsel & Sec. (Age 60)
- Mr. Anthony Zezzo II, Exec. VP & Bus. Unit Leader of Infectious Disease (Age 65)
- Mr. Brian L. Smith, Vice Chairman & EVP of Innovation - DNA Genotek, Inc. (Age 60)
- Mr. Roberto E. Cuca, CFO & Principal Accounting Officer (Age 51)
Who are OraSure Technologies' major shareholders?
OraSure Technologies' stock is owned by a number of of institutional and retail investors. Top institutional investors include BlackRock Inc. (15.22%), Renaissance Technologies LLC (8.00%), Vanguard Group Inc. (5.49%), D. E. Shaw & Co. Inc. (4.81%), Nuveen Asset Management LLC (2.27%) and Systematic Financial Management LP (2.18%). Company insiders that own OraSure Technologies stock include Brian Smith, Charles W Patrick, Douglas A Michels, Jack E Jerrett, Mara G Aspinall, Roberto Cuca and Stephen S Phd Tang. View Institutional Ownership Trends for OraSure Technologies.
Which institutional investors are selling OraSure Technologies stock?
OSUR stock was sold by a variety of institutional investors in the last quarter, including Vanguard Group Inc., Wells Fargo & Company MN, Invesco Ltd., Russell Investments Group Ltd., Sicart Associates LLC, First Quadrant L P CA, A.R.T. Advisors LLC and SG Americas Securities LLC. View Insider Buying and Selling for OraSure Technologies.
Which institutional investors are buying OraSure Technologies stock?
OSUR stock was acquired by a variety of institutional investors in the last quarter, including Nuveen Asset Management LLC, D. E. Shaw & Co. Inc., Morgan Stanley, Renaissance Technologies LLC, Citadel Advisors LLC, Marshall Wace LLP, BlackRock Inc. and Systematic Financial Management LP. Company insiders that have bought OraSure Technologies stock in the last two years include Jack E Jerrett, Mara G Aspinall, Roberto Cuca and Stephen S Phd Tang. View Insider Buying and Selling for OraSure Technologies.
How do I buy shares of OraSure Technologies?
Shares of OSUR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.
What is OraSure Technologies' stock price today?
One share of OSUR stock can currently be purchased for approximately $7.64.
How big of a company is OraSure Technologies?
OraSure Technologies has a market capitalization of $471.58 million and generates $181.74 million in revenue each year. The medical instruments supplier earns $20.40 million in net income (profit) each year or $0.50 on an earnings per share basis. OraSure Technologies employs 398 workers across the globe.View Additional Information About OraSure Technologies.
What is OraSure Technologies' official website?
How can I contact OraSure Technologies?
OraSure Technologies' mailing address is 220 EAST FIRST STREET, BETHLEHEM PA, 18015. The medical instruments supplier can be reached via phone at 610-882-1820 or via email at [email protected]
MarketBeat Community Rating for OraSure Technologies (NASDAQ OSUR)
MarketBeat's community ratings are surveys of what our community members think about OraSure Technologies and other stocks. Vote "Outperform" if you believe OSUR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe OSUR will underperform the S&P 500 over the long term. You may vote once every thirty days.
